AGÕæÈ˹ٷ½

STOCK TITAN

Kenvue Inc. SEC Filings

KVUE NYSE

Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Kenvue Inc.’s filings tell a story that reaches far beyond pain-relief sales and skincare ads. Inside each 10-K, investors uncover how royalty agreements with Johnson & Johnson affect margins, how product-liability reserves are set for talc and acetaminophen, and how global supply chains drive costs across Tylenol, Listerine and Aveeno. If you have ever searched for “Kenvue SEC filings explained simply,� this page is built for you.

Stock Titan combines real-time EDGAR feeds with AI-powered summaries, turning dense documents into clear insights. Whether you need the latest Kenvue quarterly earnings report 10-Q filing or a quick alert on Kenvue Form 4 insider transactions real-time, our platform delivers context in minutes, not hours. Want to explore compensation? The Kenvue proxy statement executive compensation section is parsed so you can see how management incentives align with brand growth.

Here’s what professionals track on this page:

  • Kenvue insider trading Form 4 transactions to monitor executive stock moves
  • Kenvue 8-K material events explained for recall notices or strategic updates
  • Kenvue annual report 10-K simplified to understand segment revenue and litigation risk
  • Understanding Kenvue SEC documents with AI for faster due-diligence
  • Kenvue earnings report filing analysis that compares quarter-over-quarter progress

All filings�10-K, 10-Q, 8-K, S-8, and every Kenvue executive stock transactions Form 4—arrive the moment they hit EDGAR. Our expert models surface key numbers, flag unusual language, and link each disclosure to the brands that drive value. Research the company behind your medicine cabinet with confidence.

Filing
Rhea-AI Summary

Amendment No. 2 to Schedule 13G shows that The Vanguard Group has a significant passive stake in Kenvue Inc. (KVUE) as of 30 June 2025.

  • Beneficial ownership: 233,245,730 common shares, equal to 12.14 % of outstanding stock.
  • Voting power: Sole 0; Shared 2,284,446 shares.
  • Dispositive power: Sole 223,757,686; Shared 9,488,044 shares.
  • Vanguard files under Rule 13d-1(b) as an investment adviser, indicating the holding is for investment purposes only.
  • Certification states the shares were acquired in the ordinary course and not to influence control of Kenvue.

The filing confirms strong institutional ownership from one of the world’s largest asset managers, which can enhance share-base stability and trading liquidity but does not signal any operational or strategic change for the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Filing
Rhea-AI Summary

On 14 July 2025, Kenvue Inc. (NYSE: KVUE) filed a Form 8-K disclosing three material items.

Item 2.02 � Preliminary Q2 results: A press release (Exhibit 99.1) announced select, unaudited second-quarter figures; no numbers appear in the filing. Full Q2 results and updated FY-25 guidance are scheduled for 7 Aug 2025.

Item 5.02 � Leadership change: CEO Thibaut Mongon resigned from both the CEO post and the Board effective 14 Jul 2025, qualifying for standard severance and “retirement� equity treatment. The Board appointed independent director Kirk L. Perry as interim CEO. His offer letter (Exhibit 10.1) provides (i) $1.25 million annual salary, (ii) up to $1.5 million performance-based cash award payable when a permanent CEO is installed, (iii) $5 million in equity (50% stock options, 50% RSUs) vesting after one year, and (iv) up to $25,000 legal-fee reimbursement. Perry will not join the Severance Plan and will receive no additional Board fees.

Item 8.01 � Strategic review: The Board formed a five-member Strategic Review Committee, chaired by Melanie L. Healey and advised by Centerview Partners and McKinsey & Co., to evaluate alternatives such as brand-portfolio optimization aimed at accelerating profitable growth and “unlocking inherent value.� No timeline or specific options were disclosed.

The filing includes standard forward-looking disclaimers and lists three exhibits: the offer letter, the press release, and the Inline XBRL cover page.

Investor takeaway: The sudden CEO departure injects uncertainty, yet the swift appointment of an experienced interim leader and initiation of a strategic review indicate proactive Board engagement. More clarity should emerge with Q2 earnings on 7 Aug 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
current report
-
Rhea-AI Summary

BlackRock Portfolio Management LLC filed Amendment No. 3 to Schedule 13G disclosing its beneficial ownership in iShares iBonds 2032 Term High Yield & Income ETF (CUSIP 46438G364). As of 30 June 2025, the firm reports:

  • Shares held: 280,000
  • Percent of outstanding class: 80.0%
  • Sole voting power: 280,000
  • Sole dispositive power: 280,000

The filing states the position is held in the ordinary course of business and not for the purpose of influencing control of the issuer. The large stake is attributed to specific “Reporting Business Units� of BlackRock, Inc. and excludes other disaggregated units. A related person�BlackRock Financial Management, Inc. � MTM � Consol—also owns more than 5 % of the ETF’s outstanding shares.

Because BlackRock is both the ETF sponsor and an affiliated investment adviser, its 80 % ownership indicates tight alignment of interests but also a highly concentrated float. Investors should consider potential liquidity constraints until additional shares are issued and dispersed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

On 2 July 2025, Auburn National Bancorporation (AUBN) director David E. Housel filed a Form 4 reporting two DRIP/optional cash purchases of the company’s common stock.

  • 38 shares acquired at $24.6912
  • 17 shares acquired at $23.2233

Housel’s direct holdings rose from an estimated 8,476 to 8,531 shares, a 0.6% increase, at a total outlay of roughly $1,338. No derivative securities were involved, and no Rule 10b5-1 plan was indicated.

While insider buying is generally viewed positively, the transaction sizeâ€�55 shares versus AUBN’s ~3.6 million shares outstanding—is immaterial from a valuation or liquidity standpoint. The filing nevertheless provides a nominal signal of continued board-level confidence in the bank.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

German American Bancorp, Inc. (GABC) filed a Form 4 reporting an insider equity grant. On 06/30/2025, Director Christina M. Ryan received 1,298 shares of restricted common stock at a price of $0 as part of the company’s non-employee director compensation plan. Following the award, Ryan beneficially owns 15,914.4331 shares. According to the filing, the restricted stock will vest on 07/01/2026. No derivative securities were reported, and the transaction was reported as a direct holding (ownership code “Dâ€�). The filing was signed by attorney-in-fact Bradley C. Arnett on 07/02/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

German American Bancorp, Inc. (GABC) filed a Form 4 reporting an insider equity grant. On 06/30/2025, Director Christina M. Ryan received 1,298 shares of restricted common stock at a price of $0 as part of the company’s non-employee director compensation plan. Following the award, Ryan beneficially owns 15,914.4331 shares. According to the filing, the restricted stock will vest on 07/01/2026. No derivative securities were reported, and the transaction was reported as a direct holding (ownership code “Dâ€�). The filing was signed by attorney-in-fact Bradley C. Arnett on 07/02/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Filing
Rhea-AI Summary

Kenvue has announced significant leadership changes in its Asia Pacific region. Ellie Bing Xie, current Group President of Asia Pacific, will step down from her role on July 14, 2025. She will remain with the company through August 8, 2025, to facilitate transition.

The company has appointed Anindya (Andy) Dasgupta as the new Group President, Asia Pacific, effective July 14, 2025. Dasgupta brings nearly 30 years of global consumer products industry experience, with expertise in:

  • Commercial strategy and sales
  • Marketing and business development
  • Leadership experience across Europe, US, and Asia Pacific
  • Health, nutrition, and food/beverage sectors

The Asia Pacific region is a significant market for Kenvue, contributing approximately $3 billion in Net sales in fiscal year 2024. Ms. Xie's departure qualifies as separation without "cause" under the Executive Severance Pay Plan, making her eligible for severance benefits subject to executing a release of claims and compliance with restrictive covenant obligations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Kenvue (KVUE)?

The current stock price of Kenvue (KVUE) is $21.59 as of August 1, 2025.

What is the market cap of Kenvue (KVUE)?

The market cap of Kenvue (KVUE) is approximately 41.6B.

What is Kenvue Inc.'s core business?

Kenvue Inc. is focused on delivering a broad range of consumer health products, including personal care, pain management, and wellness solutions that serve everyday needs.

How did Kenvue become an independent consumer health company?

Kenvue was spun off from Johnson & Johnson’s consumer segment, leveraging an extensive heritage of trusted brands and decades of experience in the consumer health market.

Which product segments does Kenvue operate in?

Kenvue operates in multiple segments such as cough, cold and allergy care, pain management, face and body care, oral care, and women’s health, addressing a wide spectrum of health needs.

What are some of Kenvue’s flagship brands?

The company’s portfolio includes globally recognized brands like Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena, each playing a vital role in everyday consumer care.

How does Kenvue maintain its market position in a competitive industry?

Kenvue leverages a strong heritage, continuous research and development, and innovative technologies, ensuring its products are both effective and trusted in the crowded consumer health landscape.

What role does innovation play in Kenvue’s product development?

Innovation is central to Kenvue’s business model; the company invests heavily in R&D to develop science-backed products, using advanced technologies to enhance product efficacy and consumer trust.

How does Kenvue address changing consumer preferences?

By actively integrating market research and consumer feedback into their product development, Kenvue continuously adapts its offerings to meet evolving health and wellness needs.

What distinguishes Kenvue in the consumer health industry?

Kenvue stands out due to its comprehensive range of trusted brands, a strong foundation in scientific research, and a commitment to delivering accessible, everyday health solutions.
Kenvue Inc.

NYSE:KVUE

KVUE Rankings

KVUE Stock Data

41.62B
1.92B
0.04%
102.41%
1.97%
Household & Personal Products
Perfumes, Cosmetics & Other Toilet Preparations
United States
SUMMIT